CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 56 enrolled
Drug / intervention
NAFT500 (pediatric) +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01712360
NCT01712360Phase 4Completed
CompareCT.gov

An Open-Label, Multi-Center, Multiple-Application Pharmacokinetic Study of NAFT-500 in Pediatric Subjects With Tinea Cruris and Tinea Pedis and NAFT-600 in Pediatric Subjects With Tinea Pedis

Merz North America, Inc.·interventional·Posted Oct 23, 2012·Updated Jul 14, 2016

In Brief

A Phase 4 clinical trial evaluating NAFT500 (pediatric), NAFT600 (pediatric), and 2 other interventions for Tinea Pedis and Tinea Cruris. Completed, enrolled 56 participants across 4 sites in 3 countries.

Detailed Summary

This study is being done to see how the body is affected when a study drug is applied to both feet if the subject has athlete's foot or to both feet and the groin area if the subject has both athlete's foot and jock itch. Safety of the drug and how well the drug works will also be measured.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTinea Pedis, Tinea Cruris
CountriesDominican Republic, Honduras, United States
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 23, 2012
Enrollment StartOct 1, 2012
Primary CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 13.7 years ago

Interventions

NAFT500 (pediatric)drug

Applied to both feet and groin area

NAFT600 (pediatric)drug

Applied to both feet only

NAFT500 (adult)drug

Applied to both feet and groin area

NAFT600 (adult)drug

Applied to both feet